Agreement No.: 75A50122C00081 BETWEEN

Exhibit 10.3

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

Other Transaction Agreement No. 75A50122C00081

Amendment No. P00002

OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR)

Agreement No.: 75A50122C00081

BETWEEN

VIR BIOTECHNOLOGY, INC

0000 XXXXX XXXXXX, XXXXX 000 XXX XXXXXXXXX, XX 00000

AND

THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES

BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY

000 XXXXXXXXXXXX XXXXXX, XX X000 XXXXXXXXXX, XX 00000

CONCERNING

Pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens of pandemic potential

Agreement No.: 75A50122C00081

Amendment No. P00002

Effective Date of Amendment: This Amendment No. P00002 (the “Amendment”) will be effective upon last signature in Section III.

Total Amount of the Agreement is unchanged at [***].

Government Share of Total Amount of the Agreement remains unchanged and is not to exceed

$1,000,000,000.

Recipient Share of Total Amount of the Agreement is unchanged at [***].

Current Government commitment is uchanged at $116,300,401.

Current Recipient commitment is unchanged at [***].

Authority: Section 319L of the Public Health Service Act, 42 USC 247d-7e.

OT No. 75A50122C00081

Page 1

Other Transaction Agreement No. 75A50122C00081

Amendment No. P00002

Line of Accounting and Appropriation:

CLIN			PRISM line item			Title			Requisition (OS)			Appropriation Year			CAN			Object Class			Amt. (Govt Share)			Changed or Unchanged
0001			0001			Base Period: VIR-2482- 4002 PENNISULA Phase 2 study			[***]			2022			[***]			25103			$50,000,000.00			Unchanged
0001			0001			Base Period: VIR-2482- 4002 PENNISULA Phase 2 study			[***]			2022			[***]			25103			$5,000,000.00			Unchanged
0001			0001			VIR-2482-4002 PENNISULA Phase 2 study			[***]			2023			[***]			25106			$11,249,523.00			Unchanged
0013			0002			Option 12- FASTx VIR- 7229			[***]			2023			[***]			25106			$40,000,000.00			Unchanged
0014			0003			Option 12- FASTx [***]			[***]			2023			[***]			25106			$2,976,862.50			Unchanged
0014			0004			Option 12- FASTx [***]			[***]			2023			[***]			25106			$7,074,015.50			Unchanged
Total																					$116,300,401.00			Unchanged

I.AMENDMENT PURPOSE: The purpose of this amendment is to:

a.Revise the language in Amendment 1, Amendment Changes, paragraph F From:

[***]

To:

[***]

b.Update the term of the agreement in line with Option 12 period of performance.

II.AMENDMENT CHANGES:

a.[***]

OT No. 75A50122C00081

Page 2

Other Transaction Agreement No. 75A50122C00081

Amendment No. P00002

b.Article II: Term, Section A, Paragraph 1 shall be deleted and replaced with “The Term of this Agreement commences upon the effective date of September 30, 2022, and extends through July 15, 2027.”

III.EXECUTION

Capitalized terms not otherwise defined herein shall have their respective meanings in the Agreement. Except as provided in this Amendment, all terms and conditions of the Agreement, unless previously changed, remain unchanged and in full force and effect.

Acknowledged, accepted, and agreed for:

Vir Biotechnology, Inc						U.S. Department of Health & Human Services
						Administration for Strategic Preparedness & Response
						Biomedical Advanced Research & Development Authority
BY:						BY: Date: 2024.01.18 18:22:19 -05'00'
NAME: XXXXXXXX XX XXXXXX, X.XX., PH.D., MBA						NAME: [***]
TITLE: Chief Executive Officer						TITLE: [***]
DATE: January 17, 2024						DATE: January 18, 2024

OT No. 75A50122C00081

Page 3

DocuSign Envelope ID: 26D43BF3-6C19-4AFA-82D1-E8DD0186D9AC

Other Transaction Agreement No. 75A50122C00081

Amendment No. P00002

Attachment A: [***]

OT No. 75A50122C00081

Page 30